P. Houyau

Phase II study of vinorelbine in patients with androgen-independent prostate cancer.

M. Piccart, D. Chopin, Y. Humblet, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.

G. Milano, P. Canal, E. Chatelut, 1993, Journal of the National Cancer Institute.

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.

M. Ychou, E. Assenat, Y. Bécouarn, 2016 .

Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.

A. Ravaud, B. Bui, J. Mihura, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients

G. Laurent, C. Récher, L. Obéric, 2015, European journal of haematology.

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial

M. Ychou, E. Assenat, R. Guimbaud, 2022, British Journal of Cancer.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.

M. Ychou, E. Assenat, Y. Bécouarn, 2018 .

Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients

G. Laurent, C. Récher, L. Obéric, 2015, European journal of haematology.